BNTX: BioNTech Stock Rating Maintained as Price Target Adjusted | BNTX Stock News

Author's Avatar
7 days ago
Article's Main Image

On July 16, 2025, B of A Securities analyst Tazeen Ahmad maintained a "Buy" rating for BioNTech (BNTX, Financial). However, the analyst adjusted the 12-month price target for the company, lowering it from $127.00 to $126.00. Despite the slight decrease in the price target, the overall rating remains unchanged at "Buy".

The price target adjustment represents a -0.79% change from the previous target, indicating a cautious but optimistic outlook for BNTX's future performance. This updated projection by B of A Securities underscores continued confidence in BioNTech's market position and prospects.

Investors and stakeholders in BioNTech (BNTX, Financial) are advised to consider this updated analysis when making investment decisions. As of now, the "Buy" recommendation suggests that the stock is expected to perform well relative to the overall market, despite the minor adjustment in the price target.

Wall Street Analysts Forecast

1945448703431176192.png

Based on the one-year price targets offered by 20 analysts, the average target price for BioNTech SE (BNTX, Financial) is $133.40 with a high estimate of $170.30 and a low estimate of $81.77. The average target implies an upside of 20.56% from the current price of $110.65. More detailed estimate data can be found on the BioNTech SE (BNTX) Forecast page.

Based on the consensus recommendation from 21 brokerage firms, BioNTech SE's (BNTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for BioNTech SE (BNTX, Financial) in one year is $33.45, suggesting a downside of 69.77% from the current price of $110.65. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BioNTech SE (BNTX) Summary page.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.